Watertown-Based Marrow Therapeuticsm Led By Romesh Subramanian, Launches with $173 Million to Develop Treatments for Severe Blood Disorders
The biotech startup, founded by Scion Life Sciences, is developing bone marrow-targeted genetic medicines for sickle cell disease, beta thalassemia and other hematological conditions.
WATERTOWN, Mass.— Marrow Therapeutics, a biotechnology company developing genetic medicines for severe blood disorders, has launched with $173 million in combined Series A and Series B financing to advance its proprietary technology platform and develop treatments targeting bone marrow.
Founded by Scion Life Sciences, Marrow raised $53 million in Series A financing co-led by Scion Life Sciences and venBio. OrbiMed led the $120 million Series B round, which included participation from all Series A investors and new investors RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments.
The company is led by President and CEO Romesh Subramanian, alongside Tim Weeden, Chief Scientific Officer, and John Najim, Chief Operating Officer and Chief Technology Officer. Gavriel Mullokandov serves as Founder and Vice President of Corporate Development.
Marrow is developing engineered antibodies designed to deliver genetic medicine directly to bone marrow cells by targeting the transferrin receptor, known as TfR1. Its proprietary Transferrin Antibody Bioconjugate (TAB) platform is intended to deliver therapeutic payloads to bone marrow while minimizing off-target effects and addressing safety, manufacturing and patient-access challenges associated with earlier genetic medicine approaches.
The company is advancing multiple programs for blood and bone marrow disorders. Its lead candidate, MAR-101, is currently in investigational new drug (IND)-enabling studies and is designed to treat both sickle cell disease and beta thalassemia. The treatment aims to reduce BCL11a, a regulator of fetal hemoglobin, to reactivate fetal hemoglobin production.
“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders – the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes,” Subramanian said. He added that the company’s bone marrow-targeting approach is designed to deliver sustained therapeutic benefits while avoiding risks that have limited earlier treatments.
Marrow says its platform builds on experience with transferrin receptor biology and is designed to engage the receptor while avoiding unintended effects, particularly anemia risks associated with other TfR1-targeted approaches.
The company also announced additions to its board and scientific advisory board. Art Levin, founding Chief Scientific Officer of Avidity Biosciences, has joined the board, while Stuart Orkin, David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and an investigator at Boston Children’s Hospital and the Howard Hughes Medical Institute, has joined the scientific advisory board.
Mona Ashiya, General Partner at OrbiMed, said the platform’s potential to address multiple blood disorders through a single therapeutic approach makes it particularly compelling. She pointed to MAR-101’s development for both sickle cell disease and beta thalassemia as an example of the platform’s potential, alongside the company’s broader pipeline.
Aaron Kantoff, co-founder and managing partner at Scion Life Sciences, said Marrow had been built around an experienced leadership team and a platform informed by lessons from earlier TfR1 technologies. He said the company aims to advance its programs into clinical development in the coming year.
Marrow Therapeutics is developing therapies for sickle cell disease, beta thalassemia and other blood and bone marrow disorders. The company is based in Watertown, Massachusetts.



